Date: 2011-04-18
Type of information: R&D agreement
Compound:
Company: UCB (Belgium) Katholieke Universiteit Leuven (Belgium)
Therapeutic area: Immunology - Immunological diseases - Autoimmune diseases
Type agreement: R&D
Action mechanism:
Disease:
Details: UCB and the Katholieke Universiteit Leuven have signed a collaborative research agreement in the field of immunology. Within this framework, researchers from both organisations will work together closely for several years in an attempt to develop therapies for patients with serious immunological disorders. In the field of immunology, UCB markets drugs against rheumatoid arthritis. Therapies against lupus erythematosus, osteoporosis and other autoimmune diseases are already in development.
Financial terms:
Latest news:
